We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVENN
RNS Number : 3315C
AIM
14 June 2019
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") COMPANY NAME: Venn Life Sciences Holdings plc COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : Registered Office: PO Box W1J 6BD, Berkley Square House, 2(nd) Floor, Mayfair, London, W1J 8DJ Trading Office: 19 Railway Road, Dalkey, Dublin, Ireland COUNTRY OF INCORPORATION: England and Wales COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: www.vennlifesciences.com/ and with effect from Admission, www.openorphan.com COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: This is a reverse takeover under Rule 14. Open Orphan is Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in France, the Netherlands and Germany. DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): Number of ordinary shares of 0.1 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 253,493,259 Placing price per Ordinary Share: 5.6 pence The are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury. CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: Capital to be raised on admission: GBP4.5 million Anticipated market capitalisation on admission: GBP14.1 million PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: 31.1% DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: Euronext Growth FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): Directors: Brendan Buckley, Non-executive Chairman Cathal Friel, Chief Executive Officer Christian Milla, Chief Operating Officer Tony Richardson, Corporate Development Officer Michael Ryan, Senior non-executive Director Proposed Director: Maurice Treacy, Executive Director FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): Before Admission Name Number of Ordinary Percentage of issued Shares share capital Livingbridge VC LLP 13,081,337 18.3% ------------------- --------------------- Kees Groen 4,780,320 6.7% ------------------- --------------------- Calculus 4,696,461 6.6% ------------------- --------------------- After Admission Name Number of Ordinary Percentage of issued Shares share capital Cathal Friel 41,046,981 16.2% ------------------- --------------------- Tony Richardson 16,313,388 6.4% ------------------- --------------------- Livingbridge VC LLP 13,081,337 5.2% ------------------- --------------------- Miton Asset Management 8,928,571 3.5% ------------------- --------------------- Crux Asset Management 8,928,571 3.5% ------------------- --------------------- Brendan Buckley 7.845,860 3.1% ------------------- --------------------- NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: n/a (i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: (i) 31 December (ii) 31 December 2018 (iii) 30 June 2019 due 30 September 2019, 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020 EXPECTED ADMISSION DATE: 28 June 2019 NAME AND ADDRESS OF NOMINATED ADVISER: Arden Partners plc 125 Old Broad Street London EC2N 1AR NAME AND ADDRESS OF BROKER: Arden Partners plc 125 Old Broad Street London EC2N 1AR OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: A copy of the admission document containing full details about the applicant and the admission of its securities will be available on the Company's website, www.vennlifesciences.com THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY The QCA Corporate Governance Code 2018 published by the Quoted Companies Alliance DATE OF NOTIFICATION: 14 June 2019 NEW/ UPDATE: New
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
PAAGGUGWQUPBUBC
(END) Dow Jones Newswires
June 14, 2019 06:00 ET (10:00 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions